Skip to main content
Full access
Letter to the Editor
Published Online: 1 April 1999

Rapid Remission of OCD With Tramadol Hydrochloride

Publication: American Journal of Psychiatry
To the Editor: Obsessive-compulsive disorder (OCD) affects 1.9% to 3.3% of the general population in the United States (1). Specific selective serotonin reuptake inhibitors (SSRIs) are often effective in the treatment of OCD (1). However, these medications are slow to act, and many patients have an inadequate response. Opiates have been noted to be efficacious in treatment-refractory OCD (24). We describe using the analgesic tramadol in an attempt to provide rapid symptom remission in a previously untreated patient with OCD. Tramadol is an analgesic that binds to opioid receptors and inhibits the reuptake of norepinephrine and serotonin (5).
Ms. A was a 27-year-old white woman with a 10-year history of OCD. She presented approximately 5 weeks after giving birth to a healthy child. There was no history of tic disorder or OCD in her family. Because of the pain from a fourth-degree perineal tear requiring surgical repair, Ms. A was given a dose of the opiate oxycodone. She observed that her obsessions ceased entirely for several hours immediately following administration of the oxy­codone. Following the birth of her child, Ms. A’s symptoms worsened. For example, she developed time-consuming rituals around the preparation of her child’s formula and spent hours smoothing out wrinkles in crib sheets to prevent her baby from succumbing to sudden infant death syndrome. She required constant reassurance from her spouse and other family members.
At the time of presentation, Ms. A had a Yale-Brown Obsessive Compulsive Scale (6) score of 26. Because of her previous response to opiates, a regimen of tramadol was initiated. Within 24 hours, she reported by telephone that her obsessions and compulsions had diminished significantly with the tramadol, 50 mg b.i.d. A week later, her Yale-Brown Obsessive Compulsive Scale score had dropped to 19. A dose of fluoxetine, 20 mg daily, was then added (after a discussion of possible serotonergic syndrome). Three weeks later, the fluoxetine dose was increased to 40 mg daily. During the first month of treatment, Ms. A required up to 350 mg p.r.n. daily of tramadol in divided doses (50 mg–100 mg q.i.d.) to diminish her OCD symptoms; her doses of tramadol were increased by approximately 50 mg–100 mg increments weekly over the first 3 weeks because of her tolerance to the anti-obsessive effects. Side effects of tramadol consisted only of initial nausea and mild sedation. Six weeks after the initiation of the two medications, Ms. A found that she no longer required the as-needed doses of tramadol, and her Yale-Brown Obsessive Compulsive Scale score had dropped to 10.
The efficacy of SSRIs in the treatment of OCD has been well established. Tramadol may represent a useful initial treatment for patients with OCD because it has low abuse potential, low physical dependency, and mild tolerance (5), and it may provide rapid symptom reduction during SSRI titration. Controlled studies are required to demonstrate tramadol’s effectiveness in the treatment of OCD.

References

1.
McElroy SL, Phillips KA, Keck PE Jr: Obsessive compulsive spectrum disorder. J Clin Psychiatry 1994; 55(Oct suppl):33–51
2.
Warneke L: A possible new treatment approach to OCD. Can J Psychiatry 1997; 42:667–668
3.
Shapira NA, McConville BJ, Pagnucco ML, Norman AB, Keck PE Jr: Novel use of tramadol hydrochloride in the treatment of Tourette’s syndrome (letter). J Clin Psychiatry 1997; 58:174–175
4.
Shapira NA, Keck PE Jr, Goldsmith TD, McConville BJ, Eis M, McElroy SL: An open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder. Depress Anxiety 1997; 6:170–173
5.
Lee CR, McTavish D, Sorkin EM: Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs 1993; 46:331–340
6.
Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleisch­mann RL, Hill CL, Heninger GR, Charney DS: The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry 1989; 46:1006–1011

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 660a - 661
PubMed: 10200754

History

Published online: 1 April 1999
Published in print: April 1999

Authors

Affiliations

TOBY D. GOLDSMITH, M.D.
NATHAN A. SHAPIRA, M.D., PH.D.
PAUL E. KECK, JR., M.D.
Cincinnati, Ohio

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share